# Selpercatinib RET expanded access

Source: https://onco.cc/trials/nct03906331/  
OnCo record `nct03906331` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This expanded-access record concerns selpercatinib for cancers with activating RET changes. The registry now marks the program approved for marketing; this does not mean the former access program is recruiting.

## Summary

This expanded-access record concerns selpercatinib for cancers with activating RET changes. The registry now marks the program approved for marketing; this does not mean the former access program is recruiting.

Expanded access study registered as NCT03906331, sponsored by Eli Lilly and Company. No drug-development phase applies in the structured registry record. Registry status checked October 10, 2026: approved for marketing. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Last checked: 2026-10-10
- Also known as: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
- Tags: ucsf-breast-coverage; expanded-access
- Registry id: NCT03906331
- Phase: not-applicable
- Setting: Cancers with activating RET alterations
- Sponsor: Eli Lilly and Company

## Sources

- ClinicalTrials.gov NCT03906331: https://clinicaltrials.gov/study/NCT03906331
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT03906331

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Selpercatinib](https://onco.cc/drugs/selpercatinib/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct03906331.json